Professor Chartrand research is supported by the Canadian Institutes of Health Research () and the Fonds de la Recherche en Santé.
The development of a mouse model of ASA, and her team were able to test this hypothesis. Gene therapy with modern technology, it corrects the urea cycle defect in the liver and normalized growth and survival of the mice. However remained hypertensive GT treated mice ASA because. ASL required for NO production in the vascular system Supplementation of NO treated these other symptoms in the mice. ‘It is important that we show the translatability of our findings to humans, as we have to show that treatment with an NO source led to sustained normalization of blood pressure in an ASA issue,’said Dr. ‘Our data, that ASA is a human genetic model of NO deficiency and investigated that NO supplementation in ASA subjects should continue, ‘he said.Of molecules including Nano Drug Fights Breast Cancer from within without harming healthy tissueThe hope is a new drug based on nano technologies polymers are of overcoming some of these problems and offer great potential in cancer treatment.
Previous work with nanoconjugates at Cedars-Sinai has established that similar approach is also at attacking malignant brain tumors. Juliet Y Ljubimova, Contributor author of a piece of the work in a recent issue out of Cancer Res, told to the press to many of ways to improve nanobiopolymers cancer cell targeted and treatment:.